[go: up one dir, main page]

CL2007003504A1 - Compuestos derivados de indol-2-il-carbonil-piperidina, antagonistas del receptor de la v1a; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de dismenorrea, hipertension, fallo cardiaco cronico y trastornos depresivos, ent - Google Patents

Compuestos derivados de indol-2-il-carbonil-piperidina, antagonistas del receptor de la v1a; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de dismenorrea, hipertension, fallo cardiaco cronico y trastornos depresivos, ent

Info

Publication number
CL2007003504A1
CL2007003504A1 CL200703504A CL2007003504A CL2007003504A1 CL 2007003504 A1 CL2007003504 A1 CL 2007003504A1 CL 200703504 A CL200703504 A CL 200703504A CL 2007003504 A CL2007003504 A CL 2007003504A CL 2007003504 A1 CL2007003504 A1 CL 2007003504A1
Authority
CL
Chile
Prior art keywords
dismenorrea
carbonil
indol
ent
hypertension
Prior art date
Application number
CL200703504A
Other languages
English (en)
Inventor
Bissantz Christophe G Caterina
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39272414&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007003504(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2007003504A1 publication Critical patent/CL2007003504A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL200703504A 2006-12-08 2007-12-05 Compuestos derivados de indol-2-il-carbonil-piperidina, antagonistas del receptor de la v1a; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de dismenorrea, hipertension, fallo cardiaco cronico y trastornos depresivos, ent CL2007003504A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06125666 2006-12-08

Publications (1)

Publication Number Publication Date
CL2007003504A1 true CL2007003504A1 (es) 2008-07-04

Family

ID=39272414

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200703504A CL2007003504A1 (es) 2006-12-08 2007-12-05 Compuestos derivados de indol-2-il-carbonil-piperidina, antagonistas del receptor de la v1a; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de dismenorrea, hipertension, fallo cardiaco cronico y trastornos depresivos, ent

Country Status (19)

Country Link
US (3) US8076360B2 (es)
EP (1) EP2102186B1 (es)
JP (1) JP2010511659A (es)
KR (2) KR20120055716A (es)
CN (1) CN101547914A (es)
AR (1) AR064138A1 (es)
AT (1) ATE527249T1 (es)
AU (1) AU2007328993B2 (es)
BR (1) BRPI0720440A2 (es)
CA (1) CA2670139A1 (es)
CL (1) CL2007003504A1 (es)
ES (1) ES2371784T3 (es)
IL (1) IL198633A0 (es)
MX (1) MX2009005544A (es)
NO (1) NO20091831L (es)
PE (1) PE20081574A1 (es)
RU (1) RU2009120136A (es)
TW (1) TWI349667B (es)
WO (1) WO2008068183A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2642998B1 (en) 2010-11-24 2020-09-16 The Trustees of Columbia University in the City of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
WO2013166037A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of eye disorders
WO2014151959A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
US10273243B2 (en) 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
EP2968303B1 (en) 2013-03-14 2018-07-04 The Trustees of Columbia University in the City of New York Octahydrocyclopentapyrroles, their preparation and use
WO2015168286A1 (en) 2014-04-30 2015-11-05 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparaiton and use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5150201A1 (es) 1998-09-07 2002-04-29 Hoffmann La Roche Derivados de piperidina
ATE255578T1 (de) 2000-05-12 2003-12-15 Solvay Pharm Bv Piperazin- und piperidinverbindungen
HU227197B1 (en) * 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
US7582761B2 (en) 2002-10-17 2009-09-01 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP1648881A1 (en) * 2003-07-04 2006-04-26 GlaxoSmithKline S.p.A. Substituted indole ligands for the orl-1 receptor
CA2616937A1 (en) * 2005-07-29 2007-02-08 F. Hoffman-La Roche Ag Indol-3-yl-carbonyl-piperidin and piperazin derivatives
DE602007007512D1 (de) * 2006-12-08 2010-08-12 Hoffmann La Roche Als via-rezeptor-antagonisten verwendbare indole

Also Published As

Publication number Publication date
US8076360B2 (en) 2011-12-13
BRPI0720440A2 (pt) 2014-01-07
MX2009005544A (es) 2009-06-05
PE20081574A1 (es) 2008-11-22
KR20120055716A (ko) 2012-05-31
IL198633A0 (en) 2010-02-17
RU2009120136A (ru) 2011-01-20
AU2007328993A1 (en) 2008-06-12
AU2007328993B2 (en) 2012-05-10
CA2670139A1 (en) 2008-06-12
NO20091831L (no) 2009-07-07
WO2008068183A1 (en) 2008-06-12
US20080139550A1 (en) 2008-06-12
ATE527249T1 (de) 2011-10-15
KR20090078367A (ko) 2009-07-17
JP2010511659A (ja) 2010-04-15
ES2371784T3 (es) 2012-01-10
EP2102186B1 (en) 2011-10-05
US8026259B2 (en) 2011-09-27
AR064138A1 (es) 2009-03-18
CN101547914A (zh) 2009-09-30
US20080139549A1 (en) 2008-06-12
EP2102186A1 (en) 2009-09-23
US20080139552A1 (en) 2008-06-12
TW200831502A (en) 2008-08-01
TWI349667B (en) 2011-10-01

Similar Documents

Publication Publication Date Title
CL2007003441A1 (es) Compuestos derivados de 1,4-diazepam sustituido, antagonistas del receptor de orexina; composicion farmaceutica; y uso para el tratamiento o prevencion de un trastorno del sueno, para potenciar la calidad del sueno, y para tratar o controlar la obesi
CL2008000059A1 (es) Compuestos derivados de espiropiperidina-glicinamida; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hipertension, dismenorrea, fallo cardiaco cronico, ansiedad, t
EA201100133A1 (ru) Антагонисты рецепторов простагландина d
EA201001253A1 (ru) N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d
CL2008000905A1 (es) Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena.
CL2009000873A1 (es) Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b
BRPI0912362A2 (pt) antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos
IL189499A (en) Use of 2,4-diaminopyrimidines or 4-aminopyrimidines for the preparation of a medicament for the treatment of a respiratory disease mediated by a p2x3 or p2x2/3 receptor antagonist
UY31619A1 (es) Compuestos espiro como antagonistas del receptor npy y5
CL2007003504A1 (es) Compuestos derivados de indol-2-il-carbonil-piperidina, antagonistas del receptor de la v1a; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de dismenorrea, hipertension, fallo cardiaco cronico y trastornos depresivos, ent
CL2007002977A1 (es) Compuestos derivados de bifenilsulfonilos y fenil heteroaril sulfonilos, moduladores del receptor h3 de histamina; composicion farmaceutica; proceso de preparacion; y uso para el tratamiento de trastornos tales como epilepsia, depresion, obesidad, tr
CL2007001778A1 (es) Compuestos derivados de 2-pirazinacarboxamida, antagonistas/agonistas inversos selectivos de cb1; proceso de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de trastornos de ingestion de comida, diabetes tipo ii y a
PL2054411T3 (pl) Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
CL2011000071A1 (es) Compuestos derivados de oxazolopirimidinas, antagonistas del receptor edg-1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades cardiovasculares, trombosis, aterosclerosis, hipertension, diabetes, enfermedades renales, respiratorias, inflamatorias y autoinmunes, entre otras.
BRPI0811267A2 (pt) Variante de fenilanina amônia-liase procariótica, composição farmacêutica, método para o tratamento de uma doença, uso de uma variante de fenilalanina amônia-liase procariótica, método para o tratamento de uma condição, e, variante de fenilalanina amônia-liase de anabaena variabilis.
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0710232B8 (pt) composto antagonista do receptor de il-8, composição farmacêutica que compreende o dito composto e uso do mesmo para o tratamento de uma doença mediada por quimiocina
BRPI0816320A2 (pt) Composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto de combinação, e, processos para a preparação deu um composto, de uma formulação farmacêutica, e de um produto de combinação
CL2007002578A1 (es) Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
CL2008002708A1 (es) Compuestos derivados de azaciclilisoquinolinona e isoindolinona, antagonistas de histamina-3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuestos; y uso del compuesto para el tratamiento de un trastorno cognitivo,
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2013002412A1 (es) Compuestos derivados de (piperidin-4-il)-ureas; composicion farmaceutica; y uso como antagonistas del receptor grelina en el tratamiento de la obesidad, trastornos alimenticios, diabetes, caquexia causada por el cancer, insuficiencia cardiaca congestiva, entre otras.
IL187966A0 (en) New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases
WO2008018827A8 (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
CL2007003483A1 (es) Compuestos derivados de indol-2-il-carbonil-espiro-piperidina, antagonistas del receptor de la v1a; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de hipertension, dismeno